Regeneron Reports Strong 2018 Third-Quarter Results
Regeneron Pharmaceuticals, Inc., a member of The Business Council of Westchester, this week reported strong financial and operating results for the third quarter. Among other signs of growth, the company announced that EYLEA reached over $1 billion in quarterly U.S. net sales and the FDA granted priority review for Dupixent for adolescents.
3Q Highlights:
- Third quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 7% to $1.02 billion versus third quarter 2017, and third quarter 2018 EYLEA global net sales increased 11% to $1.68 billion versus third quarter 2017
- U.S. launch of Libtayo® (cemiplimab-rwlc) Injection for the treatment of patients with cutaneous squamous cell carcinoma (CSCC) underway
- U.S. launch of Dupixent® (dupilumab) Injection in patients with moderate-to-severe asthma underway
- FDA approval of EYLEA for an every 12-week dosing regimen in patients with wet age-related macular degeneration (wet AMD)
- Positive Phase 3 trial results showed that EYLEA improved diabetic retinopathy and reduced vision-threatening complications
- Positive results reported from Phase 3 Dupixent trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and Phase 3 fasinumab trial in patients with chronic pain from osteoarthritis of the knee or hip
“Regeneron continues to grow and diversify our business, while continuing to deliver very strong financial results. In addition to EYLEA reaching over $1 billion in quarterly U.S. net sales, we also made significant progress with Dupixent, a key driver of future growth, and launched Libtayo, our first immuno-oncology therapy,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. “Dupixent is now approved in the U.S. for both atopic dermatitis and asthma and under regulatory review for the treatment of adolescents with atopic dermatitis – with another submission planned in chronic rhinosinusitis with nasal polyps. We also recently reported positive Phase 3 results for EYLEA in diabetic retinopathy, and expect an FDA action on our supplemental application for this indication in the first half of 2019.”
Read the full press release here.
Similar News Items
The BCW and BCW Member Feeding Westchester recently held an important and timely community hunger and budget discussion with Westchester’s State Delegation. The senior team at Feeding Westchester provided the delegation members with an update on the work they did to provide services during the recent government shutdown. With nearly 3 million New […]
Approximately 50 Westchester school officials gathered at Southern Westchester BOCES on November 14 for the School Energy Saving Seminar hosted by the Business Council of Westchester’s (BCW) Clean Energy Action Coalition (CEAC). The morning event presented a deep dive into the energy efficiency programs and funding opportunities available from key state partners: Con Edison, the […]
The complexities of business mergers took center stage on Monday at the Business Council of Westchester’s (BCW) Valley Bank Leadership Conversation. Moderated by BCW President Marsha Gordon, Mergers in Motion: Transforming Organizations through Business Combination invited regional business leaders to share insights drawn from their experiences as strategic acquirers, owner-sellers, and trusted advisors. The event […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.